 |
KYOTO, Japan, Oct. 9, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. (https://www.regenephro.co.jp/) is excited to announce that the company has successfully developed a funding plan of total approximately 17 million dollar (2.5 billion JPY) in new Series B funding and raised 15 million dollar with the first payment. This significant investment brings the company's total funding to 30 million dollar. The funding round attracted a mix of strategic investors, including DCI Partners Co., Ltd. as a lead investor, JIC Venture Growth Investments Co., Ltd., Nippon Venture Capital CO., Ltd., TOHOKU University Venture Partners Co., Ltd., Golden Asia Fund Ventures Ltd., Mitsui Chemicals, Inc., Global Brain Corporation, Kyoto University Innovation Capital Co., Ltd., JAFCO Group Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., ASAHI KASEI CORPORATION, QB Capital, LLC who recognize the potential of Rege Nephro in delivering new treatments to patients suffering from their diseases. The newly acquired funds will be strategically used to advance the clinical trials of RN-014, our promising treatment in Phase II trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and to prepare for clinical trials in the United States. Additionally, the funding will support the completion of preclinical trials for our second innovative product, RN-032, aimed at treating Chronic Kidney Disease (CKD) through cell therapy.
Investor Statements
DCI Partners Co., Ltd.
"We are excited to announce that we are the lead investor in this round of investment from our fund. We are fully committed to supporting the growth of Rege Nephro."
JIC Venture Growth Investments Co., Ltd.
"We strongly believe that his advanced drug discovery research based on Professor Osafune's discoveries will provide new therapeutic solutions for intractable renal diseases."
Kyoto University Innovation Capital Co., Ltd.
"We are delighted that Rege Nephro, which we have supported since before the company was founded, has finally entered the clinical stage. We hope that this funding will accelerate the clinical trials and bring a new therapeutic drug to patients as soon as possible."
JAFCO Group Co., Ltd.
"We hope that this financing will further accelerate Rege Nephro research and development in iPS drug discovery and provide new treatment options for patients suffering from diseases with limited treatment options."
Mitsubishi UFJ Capital Co., Ltd.
"Our continued investment reflects our confidence in Rege Nephro's rapid progress and the potential of Professor Osafune's iPS cell technology to significantly impact medical practice."
Series B investors
DCI Partners Co., Ltd. | JIC Venture Growth Investments Co., |
Nippon Venture Capital CO., Ltd | TOHOKU University Venture Partners Co., Ltd. |
Golden Asia Fund Ventures Ltd. | Mitsui Chemicals, Inc. Global Brain Corporation |
Kyoto University Innovation Capital Co., Ltd. | JAFCO Group Co., Ltd. |
Mitsubishi UFJ Capital Co., Ltd. | QB Capital, LLC |
Industrial Technology Investment | SHIMADZU CORPORATION |
SCREEN Holdings Co., Ltd. | Chushin Venture Capital Co.,Ltd. |
SENSHU IKEDA CAPITAL CO.,LTD. | Toyo Seikan Group Holdings, Ltd. |
ASAHI KASEI CORPORATION | i-Lab CVC1 Limited Liability Partnership |
Others |
|
About Rege Nephro Co., Ltd.
Rege Nephro Co., Ltd. is a clinical-stage biotech company utilizing induced pluripotent stem cell (iPSC)-based technology from the Center for iPS Cell Research and Application (CiRA), Kyoto University. It is developing therapeutics and cell therapy for kidney, liver, and pancreas diseases.
About RN-014
Tamibarotene, under development for ADPKD, is a retinoic acid receptor (RAR) agonist expected to potently inhibit cyst formation and improve renal function. The Phase II clinical trial began in December 2023. This trial includes a pharmacokinetic (PK) phase and a randomization phase. Various safety measures have been established, including phased patient enrollment, periodic independent safety monitoring, strict criteria for dose reduction and discontinuation of the investigational drug, and criteria for discontinuation of the entire trial. There have been no significant issues at this time.
About RN-032
Cell therapy using NPCs for Chronic Kidney Disease (CKD). Nephron progenitor cells (NPCs) are cells that give rise to nephrons. Rege Nephro has been tried implanting iNPCs (NPCs induced from allogeneic human iPSCs) into the damaged kidneys, and the improvements in renal function have been confirmed in the several mouse experiments.
KYOTO, Japan, Oct. 9, 2024 /PRNewswire/ -- Rege Nephro Co., Ltd. (https://www.regenephro.co.jp/) is excited to announce that the company has successfully developed a funding plan of total approximately 17 million dollar (2.5 billion JPY) in new Series B funding and raised 15 million dollar with the first payment. This significant investment brings the company's total funding to 30 million dollar. The funding round attracted a mix of strategic investors, including DCI Partners Co., Ltd. as a lead investor, JIC Venture Growth Investments Co., Ltd., Nippon Venture Capital CO., Ltd., TOHOKU University Venture Partners Co., Ltd., Golden Asia Fund Ventures Ltd., Mitsui Chemicals, Inc., Global Brain Corporation, Kyoto University Innovation Capital Co., Ltd., JAFCO Group Co., Ltd., Mitsubishi UFJ Capital Co., Ltd., ASAHI KASEI CORPORATION, QB Capital, LLC who recognize the potential of Rege Nephro in delivering new treatments to patients suffering from their diseases. The newly acquired funds will be strategically used to advance the clinical trials of RN-014, our promising treatment in Phase II trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD), and to prepare for clinical trials in the United States. Additionally, the funding will support the completion of preclinical trials for our second innovative product, RN-032, aimed at treating Chronic Kidney Disease (CKD) through cell therapy.
Investor Statements
DCI Partners Co., Ltd.
"We are excited to announce that we are the lead investor in this round of investment from our fund. We are fully committed to supporting the growth of Rege Nephro."
JIC Venture Growth Investments Co., Ltd.
"We strongly believe that his advanced drug discovery research based on Professor Osafune's discoveries will provide new therapeutic solutions for intractable renal diseases."
Kyoto University Innovation Capital Co., Ltd.
"We are delighted that Rege Nephro, which we have supported since before the company was founded, has finally entered the clinical stage. We hope that this funding will accelerate the clinical trials and bring a new therapeutic drug to patients as soon as possible."
JAFCO Group Co., Ltd.
"We hope that this financing will further accelerate Rege Nephro research and development in iPS drug discovery and provide new treatment options for patients suffering from diseases with limited treatment options."
Mitsubishi UFJ Capital Co., Ltd.
"Our continued investment reflects our confidence in Rege Nephro's rapid progress and the potential of Professor Osafune's iPS cell technology to significantly impact medical practice."
Series B investors
DCI Partners Co., Ltd.
JIC Venture Growth Investments Co.,
Nippon Venture Capital CO., Ltd
TOHOKU University Venture Partners Co., Ltd.
Golden Asia Fund Ventures Ltd.
Mitsui Chemicals, Inc.
Global Brain Corporation
Kyoto University Innovation Capital Co., Ltd.
JAFCO Group Co., Ltd.
Mitsubishi UFJ Capital Co., Ltd.
QB Capital, LLC
Industrial Technology Investment
SHIMADZU CORPORATION
SCREEN Holdings Co., Ltd.
Chushin Venture Capital Co.,Ltd.
SENSHU IKEDA CAPITAL CO.,LTD.
Toyo Seikan Group Holdings, Ltd.
ASAHI KASEI CORPORATION
i-Lab CVC1 Limited Liability Partnership
Others
About Rege Nephro Co., Ltd.
Rege Nephro Co., Ltd. is a clinical-stage biotech company utilizing induced pluripotent stem cell (iPSC)-based technology from the Center for iPS Cell Research and Application (CiRA), Kyoto University. It is developing therapeutics and cell therapy for kidney, liver, and pancreas diseases.
About RN-014
Tamibarotene, under development for ADPKD, is a retinoic acid receptor (RAR) agonist expected to potently inhibit cyst formation and improve renal function. The Phase II clinical trial began in December 2023. This trial includes a pharmacokinetic (PK) phase and a randomization phase. Various safety measures have been established, including phased patient enrollment, periodic independent safety monitoring, strict criteria for dose reduction and discontinuation of the investigational drug, and criteria for discontinuation of the entire trial. There have been no significant issues at this time.
About RN-032
Cell therapy using NPCs for Chronic Kidney Disease (CKD). Nephron progenitor cells (NPCs) are cells that give rise to nephrons. Rege Nephro has been tried implanting iNPCs (NPCs induced from allogeneic human iPSCs) into the damaged kidneys, and the improvements in renal function have been confirmed in the several mouse experiments.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Rege Nephro Co., Ltd. Successfully Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
|
ATLANTA, April 3, 2026 /PRNewswire/ -- Precision Aviation Group (PAG), a leading global provider of aftermarket aviation and aerospace services, today announced that EFIX and PAG Australia have been added to the Safran Electrical & Power Authorized Repair Center (ARC) Network, further expanding PAG's global OEM authorized repair capabilities.
With the addition of EFIX and PAG Australia, PAG now operates five Authorized Repair Centers within the Safran Electrical & Power ARC Network for its DC Generators and GCU, reinforcing the company's commitment to providing high-quality, OEM-approved MRO support across key global regions.
The five PAG companies authorized within the Safran Electrical & Power ARC Network include:
- Precision Aviation Group (PAG) – Atlanta, Georgia, USA
- PAI Canada – British Columbia, Canada
- Tuner Aviation – Glasgow, Scotland
- EFIX – Brazil
- PAI Australia – Queensland, Australia
"This expansion reflects the continued investment we're making across our Component Services organization to meet OEM standards while supporting customers where they operate," said Jordan Webber, Vice President of Component Services at Precision Aviation Group. "Adding EFIX and PAG Australia to the Safran Electrical & Power ARC Network allows us to extend trusted, authorized repair and distribution capabilities into new regions while maintaining the quality, consistency, and reliability our customers expect."
Safran Electrical & Power is a global leader in aircraft electrical systems, and its Authorized Repair Center Network is designed to ensure consistent standards of quality, compliance, and performance across approved service providers.
The inclusion of EFIX and PAG Australia enables PAG to offer expanded regional coverage in South America and the Asia-Pacific region, reducing turnaround times while maintaining the highest standards of safety and reliability.
About Precision Aviation Group (PAG)
Precision Aviation Group (PAG) is a leading provider of maintenance, repair, and overhaul (MRO) and value-added supply chain services to the aerospace and defense industries. With 26 Repair Stations, 28 locations worldwide, 1,280 employees, and over 1.2 million square feet of production and distribution facilities, PAG offers comprehensive MRO services on more than 200,000 product lines. PAG supports operators in the Airline, Business and General Aviation (BGA), Military, and Rotary Wing markets through its Inventory Supported Maintenance, Repair, and Overhaul (ISMRO®) business model.
www.precisionaviationgroup.com
About Safran
Safran is an international high-technology group, operating in the aviation (propulsion, equipment and interiors), defense and space markets. Its core purpose is to contribute to a safer, more sustainable world, where air transport is more environmentally friendly, comfortable and accessible. Safran has a global presence, with 100,000 employees and sales of 27.3 billion euros in 2024, and holds, alone or in partnership, world or regional leadership positions in its core markets. Safran is listed on the Euronext Paris stock exchange and is part of the CAC 40 and Euro Stoxx 50 indices.
Safran Electrical & Power is one of the world's leaders in aircraft electrical systems. The company is a key player in equipment electrification and in the electric and hybrid propulsion sector. It has more than 15,500 employees across 13 different countries.
For more information: www.safran-group.com
Photo - https://mma.prnasia.com/media2/2949133/Precision_Aviation_Group__PAG_employee_holds_an_aircraft_part.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/1515200/Precision_Aviation_Group_Logo.jpg?p=medium600
ATLANTA, April 3, 2026 /PRNewswire/ -- Precision Aviation Group (PAG), a leading global provider of aftermarket aviation and aerospace services, today announced that EFIX and PAG Australia have been added to the Safran Electrical & Power Authorized Repair Center (ARC) Network, further expanding PAG's global OEM authorized repair capabilities.
With the addition of EFIX and PAG Australia, PAG now operates five Authorized Repair Centers within the Safran Electrical & Power ARC Network for its DC Generators and GCU, reinforcing the company's commitment to providing high-quality, OEM-approved MRO support across key global regions.
The five PAG companies authorized within the Safran Electrical & Power ARC Network include:
- Precision Aviation Group (PAG) – Atlanta, Georgia, USA
- PAI Canada – British Columbia, Canada
- Tuner Aviation – Glasgow, Scotland
- EFIX – Brazil
- PAI Australia – Queensland, Australia
"This expansion reflects the continued investment we're making across our Component Services organization to meet OEM standards while supporting customers where they operate," said Jordan Webber, Vice President of Component Services at Precision Aviation Group. "Adding EFIX and PAG Australia to the Safran Electrical & Power ARC Network allows us to extend trusted, authorized repair and distribution capabilities into new regions while maintaining the quality, consistency, and reliability our customers expect."
Safran Electrical & Power is a global leader in aircraft electrical systems, and its Authorized Repair Center Network is designed to ensure consistent standards of quality, compliance, and performance across approved service providers.
The inclusion of EFIX and PAG Australia enables PAG to offer expanded regional coverage in South America and the Asia-Pacific region, reducing turnaround times while maintaining the highest standards of safety and reliability.
About Precision Aviation Group (PAG)
Precision Aviation Group (PAG) is a leading provider of maintenance, repair, and overhaul (MRO) and value-added supply chain services to the aerospace and defense industries. With 26 Repair Stations, 28 locations worldwide, 1,280 employees, and over 1.2 million square feet of production and distribution facilities, PAG offers comprehensive MRO services on more than 200,000 product lines. PAG supports operators in the Airline, Business and General Aviation (BGA), Military, and Rotary Wing markets through its Inventory Supported Maintenance, Repair, and Overhaul (ISMRO®) business model.
www.precisionaviationgroup.com
About Safran
Safran is an international high-technology group, operating in the aviation (propulsion, equipment and interiors), defense and space markets. Its core purpose is to contribute to a safer, more sustainable world, where air transport is more environmentally friendly, comfortable and accessible. Safran has a global presence, with 100,000 employees and sales of 27.3 billion euros in 2024, and holds, alone or in partnership, world or regional leadership positions in its core markets. Safran is listed on the Euronext Paris stock exchange and is part of the CAC 40 and Euro Stoxx 50 indices.
Safran Electrical & Power is one of the world's leaders in aircraft electrical systems. The company is a key player in equipment electrification and in the electric and hybrid propulsion sector. It has more than 15,500 employees across 13 different countries.
For more information: www.safran-group.com
Photo - https://mma.prnasia.com/media2/2949133/Precision_Aviation_Group__PAG_employee_holds_an_aircraft_part.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/1515200/Precision_Aviation_Group_Logo.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Precision Aviation Group Expands Safran Electrical & Power Authorized Repair Center Network to Five Global Facilities
